Showing results (1001-1010 of 3,886) with videos related to
Sort By:
Pageof 389
Cancer Biology & Therapy|December 14, 2020
HMGA2 promotes breast cancer metastasis by modulating Hippo-YAP signaling pathwayJianxin Xu, Xuejiao Fang, Luye Long, et al.Cancer Biology & Therapy|September 17, 2016
A retrospective analysis of the role of adjuvant radiotherapy in the treatment of cutaneous melanomaAaron Baker, Fabian Camacho, Genevieve Andrews, et al.Cancer Biology & Therapy|September 17, 2016
Comparative protein profiling of B16 mouse melanoma cells susceptible and non-susceptible to alphavirus infection: Effect of the tumor microenvironmentJelena Vasilevska, Gustavo Antonio De Souza, Maria Stensland, et al.Cancer Biology & Therapy|September 21, 2016
Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via ZebJacklynn V Egger, Maria V Lane, Lisa A Antonucci, et al.Cancer Biology & Therapy|September 23, 2016
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell linesMaria Cosenza, Monica Civallero, Stefania Fiorcari, et al.Cancer Biology & Therapy|May 27, 2017
Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trialWei Lu, Xin-Li Jin, Chao Yang, et al.Cancer Biology & Therapy|September 10, 2016
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic siteTindara Franchina, Alessandro Russo, Giuseppina Rosaria Ricciardi, et al.Cancer Biology & Therapy|October 27, 2021
NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interactionChidiebere U Awah, Jan Winter, Claudiane M Mazdoom, et al.Cancer Biology & Therapy|February 7, 2022
Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literatureDaniel S Lefler, Marni Brisson Tierno, Babar BashirCancer Biology & Therapy|February 7, 2022
Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activomeKristi Y Lee, Cindy H Chau, Douglas K Price, et al.Pageof 389